We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$396M
AUM Growth
+$117M
Cap. Flow
+$131M
Cap. Flow %
33.06%
Top 10 Hldgs %
59.9%
Holding
91
New
22
Increased
27
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.78M
2
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$6.98M
3
OCUL icon
Ocular Therapeutix
OCUL
+$5.62M
4
BBIO icon
BridgeBio Pharma
BBIO
+$5.6M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.42M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$6.29M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.74M
3
XLRN
Acceleron Pharma
XLRN
+$2.57M
4
MGNX icon
MacroGenics
MGNX
+$2.15M
5
EPIX
ESSA Pharma
EPIX
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 55.88%
2 Financials 4.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
51
Zymeworks
ZYME
$1.76B
$1.13M 0.28%
38,814
+8,814
+29% +$293K
CELL
52
DELISTED
PhenomeX Inc. Common Stock
CELL
$1.08M 0.27%
+55,000
New +$2.09M
FOLD
53
DELISTED
Amicus Therapeutics
FOLD
$1.06M 0.27%
+111,400
New +$1.14M
LKFT
54
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
$1.05M 0.27%
20,000
– –
BHVN
55
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.04M 0.26%
+7,500
New +$936K
RCOR
56
DELISTED
Renovacor, Inc.
RCOR
$1.04M 0.26%
+115,000
New +$1.12M
KDNY
57
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$949K 0.24%
74,341
-125,659
-63% -$1.65M
LUNG icon
58
Pulmonx
LUNG
$57.4M
$900K 0.23%
25,000
-35,000
-58% -$1.38M
IMTXW
59
DELISTED
Immatics N.V. Warrants
IMTXW
$800K 0.2%
190,000
– –
ACHL
60
DELISTED
Achilles Therapeutics
ACHL
$779K 0.2%
100,000
+20,000
+25% +$132K
IPHA
61
Innate Pharma
IPHA
$164M
$771K 0.19%
+125,000
New +$539K
XENE icon
62
Xenon Pharmaceuticals
XENE
$6.49B
$764K 0.19%
+50,000
New +$869K
TNGX icon
63
Tango Therapeutics
TNGX
$4.54B
$647K 0.16%
50,000
-50,000
-50% -$599K
CTMX icon
64
CytomX Therapeutics
CTMX
$771M
$636K 0.16%
125,000
+50,000
+67% +$268K
SKINW
65
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
$498K 0.13%
34,400
-10,600
-24% -$114K
KROS icon
66
Keros Therapeutics
KROS
$211M
$495K 0.13%
+12,500
New +$445K
ASLN
67
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$445K 0.11%
+6,250
New +$711K
IMVT icon
68
CALL
Immunovant
IMVT
$8.23B
$261K 0.07%
30,000
– –
CRVS icon
69
Corvus Pharmaceuticals
CRVS
$1.2B
$242K 0.06%
+50,000
New +$148K
RCOR.WS
70
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$60K 0.02%
+75,000
New +$58.5K
MSACW
71
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$24K 0.01%
33,333
– –
ALNY icon
72
CALL
Alnylam Pharmaceuticals
ALNY
$36.4B
– –
-25,000
Closed -$4.24M
APLS
73
DELISTED
Apellis Pharmaceuticals
APLS
– –
-10,000
Closed -$632K
ARKG icon
74
PUT
ARK Genomic Revolution ETF
ARKG
$1.54B
– –
-225,000
Closed -$20.8M
AXSM icon
75
Axsome Therapeutics
AXSM
$11.7B
– –
-25,000
Closed -$1.69M
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Affinity Asset Advisors held 91 positions worth $396M, up 42% from $279M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Affinity Asset Advisors deployed $131M of net new capital in Q3 2021, opening 22 new positions and adding to 27 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 68% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Zentalis Pharmaceuticals, an estimated $3.74M trimmed.

  • Affinity Asset Advisors's largest Q3 2021 buy was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q3 2021, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q3 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $3.74M.
  • Affinity Asset Advisors fully exited Protagonist Therapeutics in Q3 2021, selling an estimated $6.29M.
  • Affinity Asset Advisors's ten largest holdings make up 60% of its $396M portfolio in Q3 2021.
  • Affinity Asset Advisors opened 22 new positions and closed 18 in Q3 2021.
  • Affinity Asset Advisors's portfolio value rose 42% quarter-over-quarter to $396M.

Based on Affinity Asset Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.